[HLBANK] YoY Annualized Quarter Result on 31-Mar-2022 [#3]

Announcement Date
30-May-2022
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2022
Quarter
31-Mar-2022 [#3]
Profit Trend
QoQ- -0.57%
YoY- 9.69%
View:
Show?
Annualized Quarter Result
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Revenue 5,725,878 5,843,129 5,465,350 5,512,776 4,775,602 4,744,014 4,884,334 2.68%
PBT 5,136,613 4,781,673 4,199,296 3,528,437 3,120,953 3,270,654 3,291,489 7.69%
Tax -920,326 -843,648 -1,023,772 -633,560 -554,044 -566,576 -608,729 7.12%
NP 4,216,286 3,938,025 3,175,524 2,894,877 2,566,909 2,704,078 2,682,760 7.81%
-
NP to SH 4,216,286 3,938,025 3,175,524 2,894,877 2,566,909 2,704,078 2,682,760 7.81%
-
Tax Rate 17.92% 17.64% 24.38% 17.96% 17.75% 17.32% 18.49% -
Total Cost 1,509,592 1,905,104 2,289,826 2,617,898 2,208,693 2,039,936 2,201,574 -6.08%
-
Net Worth 36,232,826 32,922,045 30,351,463 28,539,430 26,360,066 24,898,371 23,340,592 7.59%
Dividend
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Div 683,122 600,941 491,521 403,455 436,605 436,454 436,400 7.74%
Div Payout % 16.20% 15.26% 15.48% 13.94% 17.01% 16.14% 16.27% -
Equity
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Net Worth 36,232,826 32,922,045 30,351,463 28,539,430 26,360,066 24,898,371 23,340,592 7.59%
NOSH 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 2,167,718 0.00%
Ratio Analysis
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
NP Margin 73.64% 67.40% 58.10% 52.51% 53.75% 57.00% 54.93% -
ROE 11.64% 11.96% 10.46% 10.14% 9.74% 10.86% 11.49% -
Per Share
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
RPS 279.40 285.22 266.86 269.27 233.34 231.88 238.77 2.65%
EPS 205.73 192.23 155.05 141.40 125.43 132.17 131.15 7.78%
DPS 33.33 29.33 24.00 19.71 21.33 21.33 21.33 7.71%
NAPS 17.68 16.07 14.82 13.94 12.88 12.17 11.41 7.56%
Adjusted Per Share Value based on latest NOSH - 2,167,718
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
RPS 264.14 269.55 252.12 254.31 220.31 218.85 225.32 2.68%
EPS 194.50 181.67 146.49 133.54 118.42 124.74 123.76 7.81%
DPS 31.51 27.72 22.67 18.61 20.14 20.13 20.13 7.74%
NAPS 16.7147 15.1874 14.0016 13.1657 12.1603 11.486 10.7674 7.59%
Price Multiplier on Financial Quarter End Date
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Date 29/03/24 31/03/23 31/03/22 31/03/21 31/03/20 29/03/19 30/03/18 -
Price 19.38 20.22 20.20 18.70 13.46 20.30 18.80 -
P/RPS 6.94 7.09 7.57 6.94 5.77 8.75 7.87 -2.07%
P/EPS 9.42 10.52 13.03 13.22 10.73 15.36 14.34 -6.75%
EY 10.62 9.51 7.68 7.56 9.32 6.51 6.98 7.23%
DY 1.72 1.45 1.19 1.05 1.58 1.05 1.13 7.24%
P/NAPS 1.10 1.26 1.36 1.34 1.05 1.67 1.65 -6.52%
Price Multiplier on Announcement Date
31/03/24 31/03/23 31/03/22 31/03/21 31/03/20 31/03/19 31/03/18 CAGR
Date 30/05/24 31/05/23 30/05/22 27/05/21 29/05/20 28/05/19 30/05/18 -
Price 19.26 19.54 21.12 17.90 13.66 18.94 18.60 -
P/RPS 6.89 6.85 7.91 6.65 5.85 8.17 7.79 -2.02%
P/EPS 9.36 10.17 13.62 12.66 10.89 14.33 14.18 -6.68%
EY 10.68 9.84 7.34 7.90 9.18 6.98 7.05 7.16%
DY 1.73 1.50 1.14 1.10 1.56 1.13 1.15 7.03%
P/NAPS 1.09 1.22 1.43 1.28 1.06 1.56 1.63 -6.48%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment